LC-MSMS of the MHC-I immunopeptidome of AML cell lines
Ontology highlight
ABSTRACT: The hypomethylating agent 5-azacytidine (AZA) is the first-line induction therapy for AML patients unsuitable for intensive chemotherapy. The anti-tumor effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) deriving from hypermethylated genomic regions such as cancer-testis antigens (CTAs), or endogenous retroelements (EREs). However, clear evidence supporting higher ERE MAPs presentation after AZA treatment in AML is lacking. Therefore, we examined the immunopeptidome of four AML cell lines treated with AZA through a proteogenomic approach to validate this hypothesis.
INSTRUMENT(S): Orbitrap Exploris 480
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Blood Cell
DISEASE(S): Acute Myeloid Leukemia
SUBMITTER: Courcelles Mathieu
LAB HEAD: Pierre Thibault
PROVIDER: PXD038663 | Pride | 2024-04-17
REPOSITORIES: Pride
ACCESS DATA